 Failure of several drugs in Phase III clinical trials has led to AD prevention and early intervention for onset AD treatment endeavours.Passive anti-Aβ MAB treatment can be used for preventive attempts to modify AD progression before it causes extensive brain damage and symptoms.Trials using MAB treatment for patients positive for genetic risk factors, and elderly patients positive for indicators of AD are underway.